{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:57Z","timestamp":1791685377608,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shizuoka Prefecture"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40801-024-00426-1","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T12:01:31Z","timestamp":1715342491000},"page":"317-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of Combined Statin and Fibrate Therapy: Risks of Liver Injury and Acute Kidney Injury in a Cohort Study from the Shizuoka Kokuho Database"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1392-8251","authenticated-orcid":false,"given":"Yohei","family":"Sobukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-3993","authenticated-orcid":false,"given":"Taichi","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2566-9839","authenticated-orcid":false,"given":"Daito","family":"Funaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":false,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"426_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/HCR.0b013e318192754e","volume":"29","author":"E Dembowski","year":"2009","unstructured":"Dembowski E, Davidson MH. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev. 2009;29:2\u201312.","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"426_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-8703(00)90033-4","volume":"139","author":"RS Blumenthal","year":"2000","unstructured":"Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J. 2000;139:577\u201383.","journal-title":"Am Heart J"},{"key":"426_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/jama.279.20.1643","volume":"279","author":"RS Rosenson","year":"1998","unstructured":"Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. JAMA. 1998;279:1643\u201350.","journal-title":"JAMA"},{"key":"426_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(03)00239-9","volume":"173","author":"RS Rosenson","year":"2004","unstructured":"Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004;173:1\u201312.","journal-title":"Atherosclerosis"},{"key":"426_CR5","doi-asserted-by":"publisher","first-page":"3J","DOI":"10.1016\/S0002-9149(98)00423-8","volume":"82","author":"M Farnier","year":"1998","unstructured":"Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998;82:3J-10J.","journal-title":"Am J Cardiol"},{"key":"426_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267\u201378.","journal-title":"Lancet"},{"key":"426_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390.","journal-title":"Lancet"},{"key":"426_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"J Armitage","year":"2019","unstructured":"Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407\u201315.","journal-title":"Lancet"},{"key":"426_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626\u201335.","journal-title":"Lancet"},{"key":"426_CR10","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","volume":"65","author":"GG Schwartz","year":"2015","unstructured":"Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"426_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease. Circulation. 2007;115:450\u20138.","journal-title":"Circulation"},{"key":"426_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237\u201345.","journal-title":"N Engl J Med"},{"key":"426_CR13","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.2174\/1381612811319170020","volume":"19","author":"N Katsiki","year":"2013","unstructured":"Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013;19:3124\u201331.","journal-title":"Curr Pharm Des"},{"key":"426_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-019-0845-x","volume":"18","author":"S Ida","year":"2019","unstructured":"Ida S, Kaneko R, Murata K. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18:38. https:\/\/doi.org\/10.1186\/s12933-019-0845-x.","journal-title":"Cardiovasc Diabetol"},{"key":"426_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","volume":"10","author":"LD Averbukh","year":"2022","unstructured":"Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced liver injury patterns: a clinical review. J Clin Transl Hepatol. 2022;10:543\u201352.","journal-title":"J Clin Transl Hepatol"},{"key":"426_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1345\/aph.10228","volume":"35","author":"MA Omar","year":"2001","unstructured":"Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35:1096\u2013107.","journal-title":"Ann Pharmacother"},{"key":"426_CR17","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD. Statin-associated myopathy. JAMA. 2003;289:1681.","journal-title":"JAMA"},{"key":"426_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020390","volume":"99","author":"J Zhou","year":"2020","unstructured":"Zhou J, Li D, Cheng Q. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus. Medicine. 2020;99: e20390.","journal-title":"Medicine"},{"key":"426_CR19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00228-009-0723-7","volume":"65","author":"J Wu","year":"2009","unstructured":"Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009;65:1169\u201374. https:\/\/doi.org\/10.1007\/s00228-009-0723-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"426_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/bmj.323.7309.359","volume":"323","author":"F Charatan","year":"2001","unstructured":"Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ. 2001;323:359.","journal-title":"BMJ"},{"key":"426_CR21","unstructured":"Pharmaceuticals and Medical Devices Agency. Medical drug approval information. https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0019.html. Accessed 28 Dec 2023."},{"key":"426_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med"},{"key":"426_CR23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ijcard.2016.06.234","volume":"221","author":"S Zhao","year":"2016","unstructured":"Zhao S, Wang F, Dai Y, Lin L, Tong Q, Liao Y, et al. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Int J Cardiol. 2016;221:832\u20136.","journal-title":"Int J Cardiol"},{"key":"426_CR24","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","volume":"292","author":"DJ Graham","year":"2004","unstructured":"Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585\u201390.","journal-title":"JAMA"},{"key":"426_CR25","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.amjcard.2010.07.041","volume":"106","author":"C Enger","year":"2010","unstructured":"Enger C, Gately R, Ming EE, Niemcryk SJ, Williams L, McAfee AT. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol. 2010;106:1594\u2013601.","journal-title":"Am J Cardiol"},{"key":"426_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.1365-2796.2000.00646.x","volume":"247","author":"D Gavish","year":"2000","unstructured":"Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med. 2000;247:563\u20139.","journal-title":"J Intern Med"},{"key":"426_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejim.2008.06.009","volume":"20","author":"T Meas","year":"2009","unstructured":"Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, K\u00e9vorkian JP, et al. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. Eur J Intern Med. 2009;20:197\u2013200.","journal-title":"Eur J Intern Med"},{"key":"426_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2188\/jea.JE20200480","volume":"32","author":"E Nakatani","year":"2022","unstructured":"Nakatani E, Tabara Y, Sato Y, Tsuchiya A, Miyachi Y. Data Resource Profile of Shizuoka Kokuho Database (SKDB) using integrated health- and care-insurance claims and health checkups: the Shizuoka Study. J Epidemiol. 2022;32:391\u2013400.","journal-title":"J Epidemiol"},{"key":"426_CR29","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1227\/neu.0000000000002558","volume":"93","author":"A Miyakoshi","year":"2023","unstructured":"Miyakoshi A, Nakatani E, Kaneda H, Hawke P, Sasaki H, Urano T, et al. Administration of tranexamic acid after burr hole craniotomy reduced postoperative recurrence of chronic subdural hematoma in a Japanese regional population. Neurosurgery. 2023;93:1160\u20137.","journal-title":"Neurosurgery"},{"key":"426_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jdin.2022.12.002","volume":"11","author":"N Ubukata","year":"2023","unstructured":"Ubukata N, Nakatani E, Hashizume H, Sasaki H, Miyachi Y. Risk factors and drugs that trigger the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based cohort study using the Shizuoka Kokuho database. JAAD Int. 2023;11:24\u201332.","journal-title":"JAAD Int"},{"key":"426_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jdin.2023.04.007","volume":"12","author":"H Hashizume","year":"2023","unstructured":"Hashizume H, Nakatani E, Sasaki H, Miyachi Y. Hydrochlorothiazide increases risk of nonmelanoma skin cancer in an elderly Japanese cohort with hypertension: the Shizuoka Study. JAAD Int. 2023;12:49\u201357.","journal-title":"JAAD Int"},{"key":"426_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/1940-6207.CAPR-21-0123","volume":"14","author":"K Saito","year":"2021","unstructured":"Saito K, Sato Y, Nakatani E, Kaneda H, Yamamoto S, Miyachi Y, et al. Statin exposure and pancreatic cancer incidence: a Japanese regional population-based cohort study, the Shizuoka study. Cancer Prev Res. 2021;14:863\u201372.","journal-title":"Cancer Prev Res"},{"key":"426_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295052","volume":"18","author":"D Funaki","year":"2023","unstructured":"Funaki D, Kaneda H, Miyakoshi A, Saito K, Sasaki H, Nakatani E. Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality. PLoS\u00a0One. 2023;18: e0295052.","journal-title":"PLoS\u00a0One"},{"key":"426_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758\u201364.","journal-title":"Am J Epidemiol"},{"key":"426_CR35","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"426_CR36","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213\u201323.","journal-title":"Eur Heart J"},{"key":"426_CR37","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","volume":"27","author":"GH Gislason","year":"2006","unstructured":"Gislason GH, Rasmussen JN, Abildstr\u00f8m SZ, Gadsb\u00f8ll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153\u20138.","journal-title":"Eur Heart J"},{"key":"426_CR38","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/pds.5622","volume":"32","author":"J Tomida","year":"2023","unstructured":"Tomida J, Yoshida T, Senda S, Sato T, Nakatsuma A, Iihara N. Statin persistence and adherence among older initiators: a nationwide cohort study using the national health insurance claims database in Japan. Pharmacoepidemiol Drug Saf. 2023;32:873\u201385.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"426_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwr301","volume":"175","author":"G Danaei","year":"2012","unstructured":"Danaei G, Tavakkoli M, Hern\u00e1n MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250\u201362.","journal-title":"Am J Epidemiol"},{"key":"426_CR40","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","volume":"51","author":"J-C Ansquer","year":"2008","unstructured":"Ansquer J-C, Dalton RN, Causs\u00e9 E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904\u201313.","journal-title":"Am J Kidney Dis"},{"key":"426_CR41","doi-asserted-by":"publisher","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","volume":"156","author":"YY Zhao","year":"2012","unstructured":"Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med. 2012;156:560\u20139.","journal-title":"Ann Intern Med"},{"key":"426_CR42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","volume":"67","author":"X Su","year":"2016","unstructured":"Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67:881\u201392.","journal-title":"Am J Kidney Dis"},{"key":"426_CR43","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1681\/ASN.2013090965","volume":"25","author":"R Haynes","year":"2014","unstructured":"Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825\u201333.","journal-title":"J Am Soc Nephrol"},{"key":"426_CR44","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"J Hsia","year":"2011","unstructured":"Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg\/dl with rosuvastatin. J Am Coll Cardiol. 2011;57:1666\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"426_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00041433-200208000-00009","volume":"13","author":"M Evans","year":"2002","unstructured":"Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol. 2002;13:415\u201320.","journal-title":"Curr Opin Lipidol"},{"key":"426_CR46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1067\/mcp.2002.128469","volume":"72","author":"JT Backman","year":"2002","unstructured":"Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002;72:685\u201391.","journal-title":"Clin Pharmacol Ther"},{"key":"426_CR47","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","volume":"289","author":"DN Juurlink","year":"2003","unstructured":"Juurlink DN. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652.","journal-title":"JAMA"},{"key":"426_CR48","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/STROKEAHA.114.006866","volume":"46","author":"CE Leonard","year":"2015","unstructured":"Leonard CE, Bilker WB, Brensinger CM, Flockhart DA, Freeman CP, Kasner SE, et al. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke. 2015;46:722\u201331.","journal-title":"Stroke"},{"key":"426_CR49","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/clpt.2008.150","volume":"84","author":"H Schelleman","year":"2008","unstructured":"Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. 2008;84:581\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"426_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","volume":"11","author":"SS Bhardwaj","year":"2007","unstructured":"Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007;11:597\u2013613.","journal-title":"Clin Liver Dis"},{"key":"426_CR51","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S0002-9149(97)00430-X","volume":"80","author":"VG Athyros","year":"1997","unstructured":"Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80:608\u201313.","journal-title":"Am J Cardiol"},{"key":"426_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11095-004-9011-5","volume":"22","author":"T Prueksaritanont","year":"2005","unstructured":"Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res. 2005;22:71\u20138.","journal-title":"Pharm Res"},{"key":"426_CR53","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1177\/0091270004268044","volume":"44","author":"AJ Bergman","year":"2004","unstructured":"Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004;44:1054\u201362.","journal-title":"J Clin Pharmacol"},{"key":"426_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/00912700022008874","volume":"40","author":"W-J Pan","year":"2000","unstructured":"Pan W-J, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 2000;40:316\u201323.","journal-title":"J Clin Pharmacol"},{"key":"426_CR55","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1124\/dmd.107.015230","volume":"35","author":"TC Goosen","year":"2007","unstructured":"Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007;35:1315\u201324.","journal-title":"Drug Metab Dispos"},{"key":"426_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0149-2918(03)80089-9","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25:459\u201371.","journal-title":"Clin Ther"},{"key":"426_CR57","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1067\/mcp.2001.115542","volume":"69","author":"C Kyrklund","year":"2001","unstructured":"Kyrklund C. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001;69:340\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"426_CR58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.atherosclerosissup.2018.04.474","volume":"32","author":"N Hounslow","year":"2018","unstructured":"Hounslow N, Suganami H, Nakamura M. Pemafibrate minimally affected the systemic exposure of statins, and vice versa, in healthy male volunteers. Atheroscler Suppl. 2018;32:156\u20137.","journal-title":"Atheroscler Suppl"},{"key":"426_CR59","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0891-5849(01)00632-3","volume":"31","author":"B Qu","year":"2001","unstructured":"Qu B, Li Q-T, Wong KP, Tan TMC, Halliwell B. Mechanism of clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes. Free Radic Biol Med. 2001;31:659\u201369.","journal-title":"Free Radic Biol Med"},{"key":"426_CR60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","volume":"59","author":"T St\u00fcrmer","year":"2020","unstructured":"St\u00fcrmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson FM. Methodological considerations when analysing and interpreting real-world data. Rheumatology. 2020;59:14\u201325.","journal-title":"Rheumatology"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00426-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-024-00426-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00426-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T22:03:52Z","timestamp":1718316232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-024-00426-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1007\/s40801-024-00426-1","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"22 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The funding for this work was provided by Shizuoka Prefecture. The Shizuoka Graduate University of Public Health conducts contract research projects regarding public health in Shizuoka Prefecture, including the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yohei Sobukawa, Taichi Hatta, Daito Funaki, and Eiji Nakatani have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Ethics Committee of the Shizuoka Graduate University of Public Health approved the study protocol (#SGUPH_2021_001_059).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"We anonymized the data from the SKDB. Japanese medical ethics guidelines do not require informed consent be obtained for this type of research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"According to the terms of Shizuoka Prefecture\u2019s data use agreement with local insurers, the analyzed data cannot be provided to readers by the authors. Researchers interested in accessing this dataset may apply to Shizuoka Prefecture to request access. Please contact the staff of Shizuoka Graduate University of Public Health (e-mail: info@s-sph.ac.jp).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"YS conceived the study. YS, EN, and TH designed the study. YS performed the formal statistical analysis. YS, EN, and TH interpreted the data. DF prepared the resources, such as the master codes, for this study. YS wrote the first draft of the manuscript. YS, EN, DF, and TH contributed to the critical revision of the manuscript. All the authors have read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}